Aurobindo Pharma Limited
NSE: AUROPHARMA | Information Technology
Market Fundamentals
Stock Intelligence & News
Aurobindo Pharma Limited
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Lannett Company LLC, a wholly owned step down subsidiary of the Company announces launch of generic version of Advair Diskus® in the US". |SUBJECT: Press Release
Read Full Analysis →Aurobindo Pharma Ltd (524804)
Submission of Press Release.
Read Full Analysis →Aurobindo Pharma Limited
Aurobindo Pharma Limited has informed the Exchange about Classification of US FDA Inspection at Raleigh Plant, North Carolina, owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the Company, as Voluntary Action Indicated (VAI). |SUBJECT: General Updates
Read Full Analysis →AI-Powered Alerts for Your Portfolio
Alerfo's AI classifies every news event by type, severity, and market impact — then instantly notifies you via Email & WhatsApp only for the stocks you track.
Aurobindo Pharma Ltd (524804)
Intimation of receipt of warning letter from US FDA by Unit 1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.
Read Full Analysis →Aurobindo Pharma Limited
Aurobindo Pharma Limited has informed the Exchange that Unit I of Eugia Pharma Specialities Ltd., received a Warning Letter from US FDA |SUBJECT: General Updates
Read Full Analysis →Aurobindo Pharma Shares Tumble 2% Despite Q1 Profit Jump, Double Digit Revenue Guidance For FY27
The scrip has risen 35.19% year-to-date and 49.16% in the last 12 months. Out of 28 analysts tracking the company on Bloomberg, 19 recommend buying its shares, five have a 'hold' call, and four suggest selling it.
Read Full Analysis →Earnings call transcript: Aurobindo Pharma posts 16% Q1 FY 2027 revenue growth
Earnings call transcript: Aurobindo Pharma posts 16% Q1 FY 2027 revenue growth
Read Full Analysis →Aurobindo Pharma's Q1 Margin Story Improves; Macquarie Says Growth Picture Is Still Uneven
Macquarie On Aurobindo Pharma
Read Full Analysis →Get instant alerts when AUROPHARMA breaks news
Join investors who track Aurobindo Pharma Limited on Alerfo — free plan available.
Set Free Alert →Frequently Asked Questions
What is the current trend for AUROPHARMA?
AUROPHARMA is currently showing a volatility profile consistent with its sector peers, with sentiment being actively monitored by Alerfo news scanners.
How can I set alerts for Aurobindo Pharma Limited?
You can set real-time price and news alerts by registering on the Alerfo platform and adding AUROPHARMA to your custom watchlist.